EVA Pharma’s roots stretch back over a hundred years.

Our History

Our experienced leadership team keeps us on track.

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

Life at EVA Pharma

EVA Pharma is participating in&nbsp;WHX Dubai (formerly Arab Health), one of the region’s leading healthcare exhibitions, to share what EVA Pharma has achieved and to discuss what lies ahead for the future of the pharmaceutical field.
Let’s shape the future of healthcare together by meeting our team:
February 9-12
Stand 31.A56

thumbnail_EVAxWHX-Dubai_Ann_Q10126EVA-Website.png

EVAxWHX-Dubai_Ann_Q10126EVA-Website.png

EVA Pharma is participating in WHX Dubai

EVA Pharma is participating in&nbsp;WHX Dubai (formerly Arab Health), one of the region’s leading healthcare exhibitions, to share what EVA Pharma has achieved and to discuss what lies ahead for the future of the pharmaceutical field.
Let’s shape the future of healthcare together by meeting our team:
February 9-12
Stand 31.A56

EVA Pharma is participating in WHX Dubai!

Event

EVA Pharma is participating in WHX Dubai (formerly Arab Health), one of the region’s leading healthcare exhibitions, to share what 

WHX Dubai

Curious about where mRNA is going? Join EVA Pharma's R&amp;D scientists at APRL Shanghai sharing what it’s really like to build next-generation mRNA vaccines and therapeutics—hands-on, day by day—at the heart of our mRNA innovation hub.
&nbsp;
We’re opening up the conversation on how these capabilities are taking shape, building on the collaborations we kicked off last year with Quantoom Biosciences and DNA Script, and what it truly means to localize mRNA technologies for Africa and the Middle East.
If you’re around, join our roundtable and keynote to hear directly from the scientists driving the work.

thumbnail_Asia-Pharma-R&D-Leaders-web 1.png

Asia-Pharma-R&D-Leaders-web 1.png

2026 APRL - The 14th Asia Pharma R&D Leaders

Curious about where mRNA is going? Join EVA Pharma's R&amp;D scientists at APRL Shanghai sharing what it’s really like to build next-generation mRNA vaccines and therapeutics—hands-on, day by day—at the heart of our mRNA innovation hub.&nbsp;
We’re opening up the conversation on how these capabilities are taking shape, building on the collaborations we kicked off last year with Quantoom Biosciences and DNA Script, and what it truly means to localize mRNA technologies for Africa and the Middle East.
If you’re around, join our roundtable and keynote to hear directly from the scientists driving the work.

News and Media

Curious about where mRNA is going? Join EVA Pharma's R&D scientists at APRL Shanghai
 


EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products. &nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies. &nbsp;
 Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand. &nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 60 countries worldwide. &nbsp;

thumbnail_EVAxMIS_Ann-01-web-eng (1).png

EVAxMIS_Ann-01-web-eng (1).png

thumbnail_Screenshot 2025-10-07 123536.png

Screenshot 2025-10-07 123536.png

EVA Company Profile - 2025.pdf

Company Profile - Global

thumbnail_Screenshot 2025-12-11 150609.png

Screenshot 2025-12-11 150609.png

EVA Company Profile - saudimade SA 2025 Q4-web-Digital.pdf

Company Profile - Saudi Arabia 

thumbnail_Screenshot 2025-06-17 113128.png

Screenshot 2025-06-17 113128.png

EVA Pharma Product Portfolio 2025 Q3.pdf

Product Portfolio

thumbnail_Screenshot 2025-06-17 111006.png

Screenshot 2025-06-17 111006.png

Limitless Narturals Interactive Brochure 2025.pdf

Limitless Naturals Portfolio

thumbnail_CPHI25_webthum_SCMO.png

CPHI25_webthum_SCMO.png

Contract Manufacturing 2025-2026.pdf

Contract Manufacturing

thumbnail_Screenshot 2025-06-17 112622.png

Screenshot 2025-06-17 112622.png

MARC CPHI 2025 digital.pdf

Clinical Research

thumbnail_CPHI25_webthum_Animal-Health-Portfolio.png

CPHI25_webthum_Animal-Health-Portfolio.png

Portfolio Animal health  09 1.pdf

Animal Health Portfolio

thumbnail_Screenshot 2025-10-16 161715.png

Screenshot 2025-10-16 161715.png

EU-Product Portfolio 2025 -2026.pdf

EU- Product Portfolio

About EVA Pharma 
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products. &nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies. &nbsp;
 Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand. &nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 60 countries worldwide. &nbsp;

KSA Saudi Made localization Saudization Empowering health 
research and development

Saudi Made 2025

large_pexels-kaboompics-com-6335@2x.png

medium_pexels-kaboompics-com-6335@2x.png

small_pexels-kaboompics-com-6335@2x.png

thumbnail_pexels-kaboompics-com-6335@2x.png

pexels-kaboompics-com-6335@2x.png

Are you a Journalist or Media Representative and need information about us? Please feel free to get in touch with our PR Team

Media Contact 

thumbnail_image (3) (1).jpg

image (3) (1).jpg

EVA Pharma's High-Containment and Biologics Facilities Achieve EU-GMP Certification, Paving the Way for Enhanced Access to Critical Medications 

<div>
Under this partnership, EVA Pharma to import, market, promote and distribute BeiGene’s flagship Oncology medicines BRUKINSA and TEVIMBRA in Egypt.&nbsp; &nbsp;
DUBAI, CAIRO, Egypt - 27th March 2025 – <a href="https://evapharma.com/" target="_blank" rel="noopener">EVA Pharma</a>,&nbsp; one of the fastest-growing healthcare organizations in the Middle East and Africa, and BeiGene International GmbH (an affiliate of <a href="https://beigene.com/" target="_blank" rel="noopener">BeiGene</a> Ltd., NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd, have announced a strategic partnership to expand treatment options for cancer patients in Egypt. &nbsp; &nbsp;
Under the terms of the agreement, EVA Pharma will begin by launching BRUKINSA (zanubrutinib), a second-generation Bruton Tyrosine Kinase (BTK) inhibitor. Another medicine to be introduced under this partnership is TEVIMBRA (tislelizumab), an immunotherapy that targets the PD-1 pathway. According to the U.S. Food and Drug Administration (FDA), BRUKINSA is approved for the treatment of certain blood cancers, while TEVIMBRA is approved for the treatment of solid tumors.,1,2&nbsp;
&nbsp;
“At BeiGene, our mission is to expand access to innovative oncology treatments for patients worldwide. This partnership with EVA Pharma is a significant step toward achieving that goal in Egypt.&nbsp;
&nbsp;
By combining BeiGene’s advanced therapies, such as BRUKINSA and TEVIMBRA, with EVA Pharma’s strong regional expertise, we are forming a powerful alliance to meet the urgent needs of cancer patients. Together, we are not only delivering hope but also working to raise the standard of cancer care in Egypt and across the region,” said Mohammed Al Kapany, General Manager of BeiGene’s Middle East and Africa (MENA) region.&nbsp;
&nbsp;
“We are eager to provide cancer patients with innovative and accessible therapies. That’s why we are partnering with BeiGene — to improve patient outcomes by increasing access to critical treatments. It is also worth noting that this marks the third global pharmaceutical company to choose EVA Pharma as a partner of choice, a reflection of the trust and credibility we have built over the years,” said Dr. Amgad Talaat, Strategic Alliances Director and Saudi Arabia Cluster Head, EVA Pharma.&nbsp;
&nbsp;
<a href="https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf" target="_blank" rel="noopener">The Global Cancer Observatory (GLOBOCAN 2022) reports over 366,000 cancer cases in Egypt, with nearly 95,300 cancer-related deaths.</a>3 This partnership was established to address the significant unmet need for advanced oncology treatments in Egypt, reflecting the shared commitment of EVA Pharma and BeiGene to expand access to innovative cancer care.&nbsp;
&nbsp;
It also represents a major milestone in improving access to these innovative therapies across the region.&nbsp;
&nbsp;
Under the agreement, EVA Pharma will lead the importation, marketing, and medical promotion of BeiGene’s oncology therapies in Egypt — treatments that have shown meaningful progress in advancing cancer care. By leveraging EVA Pharma’s deep expertise in distribution, medical affairs,&nbsp;&nbsp;
and regional market dynamics, this collaboration aims to make these innovative options more accessible to patients in Egypt.&nbsp;
&nbsp;
EVA Pharma and BeiGene are also committed to supporting healthcare professionals through ongoing medical education and resources to help optimize patient outcomes. This partnership represents a significant step toward strengthening cancer care in Egypt and contributing to broader efforts to reduce the global cancer burden — delivering renewed hope to patients and their families.&nbsp;
&nbsp;
About TEVIMBRA®(tislelizumab)&nbsp;
&nbsp;
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping the body’s immune cells detect and fight tumors.&nbsp;
TEVIMBRA is the foundational asset of BeiGene’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 34 counties and regions across 66 trials, including 20 registration-enabling studies. TEVIMBRA is approved in more than 42 countries, and more than 1.3 million patients have been treated globally.&nbsp;
&nbsp;
About BRUKINSA®(zanubrutinib)&nbsp;
&nbsp;
BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues. &nbsp;
 &nbsp;
BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing. The global BRUKINSA clinical development program includes about 6,000 patients enrolled in 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 70 markets, and more than 100,000 patients have been treated globally. &nbsp;
&nbsp;
About EVA Pharma&nbsp;
&nbsp;
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind&nbsp;&nbsp;
&nbsp;
capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.&nbsp;
&nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;
&nbsp;
Guided by a relentless drive to ensure sustainable access to pressing, yet unmet, disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.&nbsp;
&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.&nbsp;
&nbsp;
For more information, please visit: <a href="http://www.evapharma.com/" target="_blank" rel="noopener">www.evapharma.com</a> &amp; <a href="https://www.evapharma.com/newsroom" target="_blank" rel="noopener">https://www.evapharma.com/newsroom</a> or follow us on <a href="https://www.facebook.com/Evapharma/" target="_blank" rel="noopener">Facebook</a>, <a href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noopener">LinkedIn</a> &amp; <a href="https://www.instagram.com/eva.pharma/" target="_blank" rel="noopener">Instagram</a>  &nbsp;
&nbsp;
About BeiGene&nbsp;
&nbsp;
BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit <a href="https://www.beigene.com/" target="_blank" rel="noopener">www.beigene.com</a> and follow us on <a href="https://www.linkedin.com/search/results/all/?fetchDeterministicClustersOnly=true&amp;heroEntityKey=urn%3Ali%3Aorganization%3A106535894&amp;keywords=beone%20medicines&amp;origin=RICH_QUERY_TYPEAHEAD_HISTORY&amp;position=0&amp;searchId=6405c2b3-1782-41dd-8a8b-fb8b6dde8a40&amp;sid=-Nh&amp;spellCorrectionEnabled=true" target="_blank" rel="noopener">LinkedIn</a>.&nbsp;
&nbsp;
Forward-Looking Statements&nbsp; &nbsp;
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s ability to deliver transformative therapies to patients with cancer; the potential of&nbsp;&nbsp;
BRUKINSA® (zanubrutinib) and TEVIMBRA® (tislelizumab) to address critical needs in oncology; the future development, regulatory approvals, and commercial success of BRUKINSA and TEVIMBRA; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.”&nbsp;
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its medicines; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approvals; BeiGene’s ability to achieve commercial success for its approved medicines and investigational drug candidates; its ability to obtain and maintain protection of intellectual property; its reliance on third parties to conduct development, manufacturing, commercialization, and other services; its limited experience in&nbsp;&nbsp;
&nbsp;
&nbsp;
obtaining regulatory approvals and commercializing pharmaceutical products; and its ability to obtain additional funding and achieve and maintain profitability.&nbsp;
&nbsp;
Additional information is available in BeiGene’s most recent quarterly report on Form 10-Q, as well as subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date hereof, and BeiGene undertakes no duty to update such information unless required by law.&nbsp;
&nbsp;
Issued by:&nbsp;
EVA Pharma, El Sharekat St., El Opera-Abdeen – Cairo - Egypt&nbsp; &nbsp; BeiGene International GmbH, Dubai Science Park, Al Barsha - Al Barsha South - Dubai - United Arab Emirates.&nbsp;
Date of Preparation:&nbsp;
26 March 2025&nbsp;
***************************************************************************************&nbsp;
References&nbsp;
<ol style="margin-top: 0in;" start="1" type="1">
<li class="MsoNormal">BRUKINSA® (zanubrutinib) - U.S. Food and Drug Administration. FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. January 19, 2023. Available at: <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma" target="_blank" rel="noopener">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma</a>&nbsp;</li>
</ol>
<ol style="margin-top: 0in;" start="2" type="1">
<li class="MsoNormal">TEVIMBRA® (tislelizumab) - U.S. Food and Drug Administration. Drug Trials Snapshots: TEVIMBRA. March 14, 2024. Available at: <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra" target="_blank" rel="noopener">https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra</a>&nbsp;</li>
</ol>
<ol style="margin-top: 0in;" start="3" type="1">
<li class="MsoNormal">International Agency for Research on Cancer. GLOBOCAN 2020: Egypt Fact Sheet. World Health Organization; 2021. Available at: <a href="https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf" target="_blank" rel="noopener">https://gco.iarc.who.int/media/globocan/factsheets/populations/818-egypt-fact-sheet.pdf</a>.&nbsp; Accessed 21 March 2025.&nbsp;</li>
</ol>
&nbsp;
END&nbsp;
&nbsp;
For media inquiries contact - BeiGene:&nbsp;&nbsp;
&nbsp;
Louise Carter Rosa Soto&nbsp;
Email: <a href="mailto:louise.carter@beigene.com" target="_blank" rel="noopener">louise.carter@beigene.com</a> Email: <a href="mailto:louise.carter@beigene.com" target="_blank" rel="noopener">rosa.soto@beigene.com</a>&nbsp;
&nbsp;
For media inquiries contact – EVA Pharma:&nbsp;&nbsp;
&nbsp;
Ahmed Ellewa&nbsp;
Email: <a href="mailto:ahmed.ellewa@evapharma.com" target="_blank" rel="noopener">ahmed.ellewa@evapharma.com</a>&nbsp;
&nbsp;
&nbsp;
&nbsp;
</div>

thumbnail_IMG_9167.JPG

IMG_9167.JPG

EVA Pharma and BeiGene Announce a Strategic Partnership to Bring Innovative Oncology Therapies to Patients in Egypt 

Cairo, Egypt – February 5, 2025 –Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding today, on the sidelines of the 2nd Vaccine and Other Health Products Manufacturing Forum for African Union Member States, organized by Africa CDC and hosted by the Egyptian United Procurement Authority (UPA) in Cairo. This collaboration aims to develop the first ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines for both human and animal health.&nbsp;
The platform, taking place in Egypt, will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify® mRNA synthesis and Ncapsulate® formulation technologies, combined with EVA Pharma’s vaccine development, top notch GMP sterile manufacturing expertise and commercialization capabilities. The collaboration addresses critical market needs, including rapid responses to infectious diseases outbreaks and routine immunizations.. The shared vision is to produce 100 million doses of RNA-based vaccines annually, fostering localization and strengthening regional autonomy in biopharmaceutical manufacturing. This collaboration will focus on developing a next generation, saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases from the source.&nbsp;
This initiative will contribute to achieve Africa CDC’s target of 60% local vaccine production by 2040 and Egypt’s ambitious goal to manufacture 385 million vaccine doses annually by 2030, establishing itself as a global leader in vaccine production. It also supports public health resilience and food security across Africa and the Middle East.&nbsp;&nbsp;
“This moment will reshape African and global health security as we know it.” Said Dr. Riad Armanious, CEO of EVA Pharma, expressing his enthusiasm. “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks. This is not tomorrow’s promise, it is today’s reality: with an operational biologics manufacturing site producing 100 million vials and 1.5 billion doses of animal health vaccine already commercialized, we have the infrastructure to streamline vaccine production using groundbreaking mRNA technology and ensuring unparalleled safety.”
According to Marc Montserrat, CEO of DNA Script,&nbsp;&nbsp;“Our collaboration with EVA Pharma and Univercells-Quantoom to implement our proprietary enzymatic DNA synthesis technology directly supports the mission to accelerate vaccine development and delivery worldwide, and more broadly aligns with our vision to make biology programmable. By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we're helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before.”&nbsp;
José Castillo, CEO of Quantoom Biosciences, added: “This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-saving vaccines and therapeutics accessible to underserved populations.”&nbsp;
Hala Audi, CEO of Unizima, echoed this sentiment: “EVA Pharma is already showing the world the power of investing in the biopharma sector to create health and wealth in Africa and the Middle East. We are proud to support the tech transfer of some of the best technology for DNA and RNA manufacturing to Egypt, as the next chapter in their growth.”&nbsp;
This MoU reflects a strong commitment to advance global health equity and foster sustainable biopharma development. By combining their strengths, the partners aim to deliver versatile, scalable, and impactful solutions. These will shape the future of healthcare in Egypt and beyond, while contributing to economic resilience and regional pandemic preparedness and response.&nbsp;
&nbsp;
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;=ENDS=&nbsp;
About EVA Pharma&nbsp;
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic products.&nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.&nbsp;
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram
&nbsp;
About EVA Pharma’s mRNA Innovation Hub&nbsp;
EVA Pharma has notably focused on localizing innovation in recent years through investing in research infrastructure and financing. The company has established an in-house research and development footprint, including its mRNA Innovation Hub, which is fully equipped to handle the complete mRNA vaccine development lifecycle—from digital sequencing to final drug formulation. This includes antigen selection, protein engineering, mRNA construct design, process development, innovative formulation delivery systems, and analytical method development.&nbsp;
&nbsp;
About DNA Script&nbsp;
DNA Script is at the forefront of transforming biological research through advanced enzymatic DNA synthesis technology. We provide pioneering solutions for DNA production, including our cutting-edge SYNTAX® DNA printer and our enzymatic synthesis technology that enables the production of longer and more complex DNA sequences. Our innovations are driving progress across critical scientific domains, including mRNA vaccine development, cell and gene therapy, and broader biomolecular research. By offering researchers unprecedented capabilities to synthesize high-quality DNA sequences, we are accelerating discoveries that have the potential to revolutionize healthcare, biotechnology, and scientific understanding.&nbsp;
&nbsp;
About Quantoom Biosciences&nbsp;
Quantoom Biosciences is leading the revolution in mRNA- and saRNA-based vaccines and therapeutics by providing turnkey solutions for (sa)mRNA &amp; LNP manufacturing. Its cutting-edge Ntensify® technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&amp;D to commercial manufacturing. Launched in 2023, Ntensify has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate® technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based drugs. Located in Belgium, Quantoom Biosciences thrives in a dynamic biotech ecosystem, driving innovation in mRNA production to make life-changing therapies available to everyone, everywhere. More info : www.quantoom.com&nbsp;
&nbsp;
About Unizima&nbsp;
Unizima is a trusted consultancy specialized in public and private partnerships for establishing bioproduction facilities and develop the workforce in emerging biotech ecosystems. As a partner to biopharma manufacturers, governments, and global health agencies, Unizima enables the sustainable production of biologics—including vaccines, monoclonal antibodies, and recombinant protein. From project inception to technology transfer and training, Unizima integrates all necessary elements to bring biomanufacturing initiatives to life. More info: www.unizima.com&nbsp;&nbsp; 
Contact details&nbsp;
EVA Pharma&nbsp;
Marina Mansour&nbsp;
Corporate communications professional&nbsp;
Marina.mansour@evapharma.com 
DNA Script
Rachel Macmaster, PhD
Director, Global Marketing
<span style="font-size: 12.0pt; line-height: 115%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">&nbsp;publicrelations@dnascript.com&nbsp;&nbsp;
&nbsp;
Quantoom Biosciences / Unizima&nbsp;
Jonathan Lecocq&nbsp;
MarCom Manager&nbsp;
j.lecocq@quantoom.com&nbsp;
+32 476 81 12 44&nbsp;
&nbsp;
Disclosure Statement&nbsp;&nbsp;
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. &nbsp;

large_WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

medium_WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

small_WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

thumbnail_WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

WhatsApp Image 2025-02-05 at 10.06.15 2.jpeg

Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences

thumbnail_Glargivin-Photo-2 (1).jpg

Glargivin-Photo-2 (1).jpg

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt 

&nbsp;
Under this royalty-free voluntary licensing agreement EVA Pharma will manufacture and supply Lenacapavir active pharmaceutical ingredient and finished pharmaceutical product.
&nbsp;
CAIRO, October 3, 2024&nbsp;–<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3735678-1&amp;h=1130473503&amp;u=http%3A%2F%2Fwww.evapharma.com%2F&amp;a=EVA+Pharma" target="_blank" rel="noopener"><span style="font-size: 11.0pt; font-family: 'IBM Plex Sans Arabic',sans-serif; mso-fareast-font-family: 'Times New Roman'; color: #007bff; border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in;">EVA Pharma</a>&nbsp;announced today a non-exclusive, royalty-free voluntary licensing agreement signed with <a href="https://www.gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries">Gilead</a>, allowing EVA Pharma to manufacture and supply generic lenacapavir in form of active pharmaceutical ingredient and finished pharmaceutical product. This agreement includes the technology transfer of know-how to make and use lenacapavir allowing for sustainable accessibility to lenacapavir in 120 high-incidence, resource-limited countries through EVA Pharma’s local manufacturing capabilities and strong foothold in Africa.
&nbsp;
The agreement covers lenacapavir for HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug-resistant HIV, as well as lenacapavir for HIV prevention (pending approval). Gilead is exploring frameworks such as the European Medicines Agency’s EU Medicines for All with the aim of expediting both U.S. FDA procedures and the attainment of WHO prequalification. This will enable EVA Pharma to submit its high-quality generic lenacapavir for multiple regulatory authorities to support demand and broaden accessibility across 120 countries.
&nbsp;
“<a href="https://www.unaids.org/sites/default/files/media_asset/2024-unaids-global-aids-update_en.pdf">The urgency of NOW</a> demands that we go fast and far to end HIV/AIDS. This goal is only reached through collective efforts, from innovation to sustainable access to medicines.” said Riad Armanious, CEO of EVA Pharma. “To this commitment we stand our ground as the sole licensee on Africa, EVA Pharma has already rolled the ball on fast-track actions towards our joint mission with Gilead. Combining Gilead’s expertise and EVA Pharma’s capabilities and reach we ensure that no one is left behind in the fight against HIV.”
&nbsp;
&nbsp;
&nbsp;
“EVA Pharma has been committed to the fight against HIV since 2003, consistently empowering governments and healthcare systems to support patient care across Africa” said Amgad Talaat, Strategic Alliances Director at EVA Pharma. “In our ongoing effort to ensure sustainable access, EVA Pharma has expanded its focus to localizing drug substance production. In collaboration with Gilead we have been setting numerous firsts in the area of generic voluntary licensing, from combatting HCV to making remdesivir available for COVID patients. And now, we embark on another significant milestone by supplying lenacapavir to patients across the continent, including South Africa for the first time” 
&nbsp;
Of the six generic manufacturers in Gilead’s voluntary licensing agreement, EVA Pharma is the sole local manufacturer in Africa. Responding to the urgency of this shared mission, EVA Pharma expects to complete lenacapavir API manufacturing by the end of 2024, following the completion of the tech-transfer from Gilead, paving the way for the production of lenacapavir finished product. The company expects to begin supplying the high-quality, African-made lenacapavir within 25 months. Leveraging its extensive pan-African reach, EVA Pharma will supply the medicine to 120 countries, with the first phase of export including 18 countries representing the highest incidence rate (about 70% of the HIV burden in the countries named in the license) to receive lenacapavir as quickly as possible. These countries are Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zambia and Zimbabwe. 
&nbsp;
&nbsp;
--end of release--
&nbsp;
&nbsp;
About EVA Pharma
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biologic product.
&nbsp;
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
&nbsp;
Guided by a relentless drive to ensure sustainable access to pressing, yet unmet, disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.
&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide.
For more information, please visit: <a href="http://www.evapharma.com/">www.evapharma.com</a> &amp; <a href="https://www.evapharma.com/newsroom">https://www.evapharma.com/newsroom</a> or follow us on <a href="https://www.facebook.com/Evapharma/" target="_blank" rel="noopener">Facebook</a>, <a href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noopener">LinkedIn</a> &amp; <a href="https://www.instagram.com/eva.pharma/" target="_blank" rel="noopener">Instagram</a> &nbsp;
&nbsp;
&nbsp;
About Gilead Sciences:
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
&nbsp;
&nbsp;
About Lenacapavir
Lenacapavir is approved in multiple countries for the treatment of adults with multi-drug-resistant HIV in combination with other antiretrovirals. The use of lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.
The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.
Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead's HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV.

large_Eva-announcment-10-gilead-for-web 1.png

medium_Eva-announcment-10-gilead-for-web 1.png

small_Eva-announcment-10-gilead-for-web 1.png

thumbnail_Eva-announcment-10-gilead-for-web 1.png

Eva-announcment-10-gilead-for-web 1.png

EVA Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High HIV Incidence and Limited Resources

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa&nbsp;
INDIANAPOLIS, CAIRO, September 4, 2024 -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. Discovered by Incyte and licensed to Lilly, baricitinib is for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.&nbsp;This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.&nbsp;
"Our commitment to expanding access to affordable and innovative medicines for people living in low- to middle-income countries continues,” said Ilya Yuffa, executive vice president and president of Lilly International. “Following our collaboration with EVA Pharma on insulin manufacturing, we are now establishing the first of its kind voluntary licensing agreement for Lilly, where the company will provide certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply baricitinib to people in 49 countries across Africa.”&nbsp; &nbsp;
“We are proud to localize the entire value chain of this critical medication on the continent, from producing high-potency baricitinib active pharmaceutical ingredient (API), to tackling complex manufacturing challenges.” said Riad Armanious, CEO of EVA Pharma.&nbsp;
EVA Pharma’s dedicated high-containment facility is set to begin sales of the locally manufactured baricitinib by 2026 to various African countries.&nbsp;
This collaboration announced today relies on both EVA’s pan-African reach and its strong local manufacturing capabilities that meet global standards, enabling Lilly to reach more people in low- to middle-income countries.&nbsp;
Since 2021, EVA Pharma has been working with Lilly to ensure a sustainable supply of life-saving medicines across several African countries. Lilly and EVA Pharma are also collaborating to expand access to affordable insulin in 56 countries, most of which are low- to middle-income, as announced in 2022.&nbsp;
About Lilly&nbsp;
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY&nbsp;
About EVA Pharma&nbsp;
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.&nbsp;
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram  &nbsp;
Cautionary Statement Regarding Forward-Looking Statements&nbsp;
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the agreement with EVA Pharma where Lilly will license certain manufacturing know-how and reflects Lilly’s current beliefs and expectations. However, there can be no assurance that the agreement will achieve Lilly’s objectives or that Lilly will execute its strategy&nbsp;

large_website-lilly-partnership.png

medium_website-lilly-partnership.png

small_website-lilly-partnership.png

thumbnail_website-lilly-partnership.png

website-lilly-partnership.png

Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries 

Egypt's Prime Minister visits EVA Pharma's state-of-the-art manufacturing complex, which is set to provide locally manufactured insulin to more than 60 countries.&nbsp;
Cairo, Egypt – September 21, 2024 – Egypt’s Prime Minister Dr. Mostafa Madbouly, accompanied by a delegation of key ministers and officials, conducted an official visit today to the EVA Pharma Pharmaceutical Manufacturing Complex in 6th of October City. The visit comes as part of the Egyptian government’s continued support for Egypt’s growing pharmaceutical sector, a critical industry in meeting both local needs and promoting medicines exportation.&nbsp;
During the visit, Dr. Madbouly and the esteemed delegation toured EVA Pharma’s state-of-the-art production facilities, certified by the European Medicines Agency (EMA) and featuring cutting-edge technologies. The manufacturing complex, inaugurated in 2017, spans 125,000 square meters and being one of the largest pharmaceutical facilities in the Middle East and Africa.&nbsp;
Dr. Khaled Abdel Ghaffar, Deputy Prime Minister for Human Development and Minister of Health and Population, highlighted the importance of the tour, including visits to other prominent national and private pharmaceutical companies. "These facilities are instrumental in advancing Egypt's pharmaceutical production capabilities, localizing high-quality medical treatments, and expanding export opportunities," said Dr. Khaled Abdel Ghaffar.&nbsp;
Dr. Ali El-Ghamrawy, chairman of the Egyptian Drug Authority (EDA), emphasized EVA Pharma’s key role in realizing Egypt's vision for localizing advanced medical treatments and vaccines, aligning with directives from President Abdel Fattah El-Sisi to deepen local manufacturing in strategic sectors.&nbsp;
Dr. Riad Armanious, CEO of EVA Pharma underlined the importance of EVA Pharma’s human capital and great capacity and said: "With over 5,000 professionals and 1 million healthcare products daily, EVA Pharma is positioned as a leader in Egypt’s pharmaceutical industry. We are committed to innovation, investing heavily in research and development to meet both local and global healthcare needs."&nbsp;&nbsp;
Dr. Riad Armanious clarified that EVA Pharma’s R&amp;D center, the largest in Egypt, focuses on clinical trials, human genome studies, as well as vaccine development. Lastly, He concluded that locally manufactured insulin is currently a top priority, aiming to local supply and exporting it to more than 60 countries.&nbsp;
&nbsp;
================================End of Press Release=============================&nbsp;
&nbsp;
&nbsp;
&nbsp;
About EVA Pharma &nbsp;
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies. &nbsp;
 &nbsp;
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand. &nbsp;
 &nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide. &nbsp;
&nbsp;
For more information, please visit: <a id="menur1gk" class="fui-Link ___1q1shib f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1s184ao f1mk8lai fnbmjn9 f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn" title="http://www.evapharma.com/" href="http://www.evapharma.com/" target="_blank" rel="noreferrer noopener" aria-label="Link www.evapharma.com">www.evapharma.com</a> &amp; <a id="menur1gm" class="fui-Link ___1q1shib f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1s184ao f1mk8lai fnbmjn9 f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn" title="https://www.evapharma.com/newsroom" href="https://www.evapharma.com/newsroom" target="_blank" rel="noreferrer noopener" aria-label="Link https://www.evapharma.com/newsroom">https://www.evapharma.com/newsroom</a> or follow us on <a id="menur1go" class="fui-Link ___1q1shib f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1s184ao f1mk8lai fnbmjn9 f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn" title="https://www.facebook.com/evapharma/" href="https://www.facebook.com/Evapharma/" target="_blank" rel="noreferrer noopener" aria-label="Link Facebook">Facebook</a>, <a id="menur1gq" class="fui-Link ___1q1shib f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1s184ao f1mk8lai fnbmjn9 f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn" title="https://www.linkedin.com/company/eva-pharma/" href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noreferrer noopener" aria-label="Link LinkedIn">LinkedIn</a> &amp; <a id="menur1gs" class="fui-Link ___1q1shib f2hkw1w f3rmtva f1ewtqcl fyind8e f1k6fduh f1w7gpdv fk6fouc fjoy568 figsok6 f1s184ao f1mk8lai fnbmjn9 f1o700av f13mvf36 f1cmlufx f9n3di6 f1ids18y f1tx3yz7 f1deo86v f1eh06m1 f1iescvh fhgqx19 f1olyrje f1p93eir f1nev41a f1h8hb77 f1lqvz6u f10aw75t fsle3fq f17ae5zn" title="https://www.instagram.com/eva.pharma/" href="https://www.instagram.com/eva.pharma/" target="_blank" rel="noreferrer noopener" aria-label="Link Instagram">Instagram</a>&nbsp;

large_AGH34309.jpg

medium_AGH34309.jpg

small_AGH34309.jpg

thumbnail_AGH34309.jpg

AGH34309.jpg

Egyptian Prime Minister Visits EVA Pharma Pharmaceutical Manufacturing Complex in 6th of October City  

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries
&nbsp;
INDIANAPOLIS and CAIRO,&nbsp; December 14, 2022 – Eli Lilly and Company (NYSE: LLY) and EVA Pharma&nbsp; announced today a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.
&nbsp;
In a first for Lilly, the company will supply its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma. Lilly will also provide a pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges – establishing the company as a trusted manufacturer of these lifesaving products in Africa.
&nbsp;
EVA Pharma expects to begin distribution of the African-made insulin products within 18 months and to reach one million people per year by 2030. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality healthcare for 30 million people living in limited -resource settings, annually, by 2030
&nbsp;
“Our new collaboration with EVA Pharma reflects Lilly’s deep commitment to making equitable and affordable access to insulin a reality for people living with diabetes in low- and middle-income countries,” said Ilya Yuffa, president of Lilly International. “This latest initiative from Lilly will empower&nbsp; local manufacturing, finishing and&nbsp; distribution of quality insulin – in Africa – which will transform communities and make life better for people throughout the continent.”
&nbsp;
“EVA Pharma is committed to empowering the fight for health and well-being as a human right,” said Riad Armanious, CEO of EVA Pharma. “People suffering from diabetes in LMICs experience daily challenges in accessing treatment. We feel blessed to collaborate with the team at Lilly. Combining our African reach, state-of-the-art facilities, and Lilly’s deep expertise in diabetes care, we aim to treat at least one million patients by 2030 who otherwise may not have access to life-saving medication.”
&nbsp;
According to the IDF Diabetes Atlas, the total number of people with diabetes in Africa is expected to increase 129% by 2045, reaching 55 million people.
&nbsp;
&nbsp;
&nbsp;
&nbsp;WHO established the Global Diabetes Compact in 2021, a global initiative to support countries in implementing effective programs for the prevention and management of diabetes, one tenet of which includes engaging with the private sector to expand access to products that will improve the lives of people living with diabetes. The dialogues with WHO encourage implementation of and accountability for the commitments and contributions toward improving access to insulin
&nbsp;
“The success of these commitments to increase access for people living with diabetes is an important step in the right direction, but global engagement will need to be translated into implementation in regions and countries,” said WHO Director for Noncommunicable Disease, Dr Bente Mikkelsen. “This is the starting point the hope is to have insulin and diabetes devices as part of Essential Benefit Packages in low- and middle- income countries towards achieving Universal Health Coverage.”
&nbsp;
&nbsp;
&nbsp;
Lilly will work with EVA Pharma to ensure that their products meet the high-quality standards set for WHO prequalification, which has become a global symbol for safety, quality and efficacy.
&nbsp;
&nbsp;
&nbsp;
&nbsp;About Lilly&nbsp;
&nbsp;
&nbsp;
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram and LinkedIn.
About EVA Pharma
EVA Pharma empowers the fight for health and well-being in communities around the world.
With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram&nbsp;&nbsp;
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about a collaboration between Lilly and EVA Pharma and its potential benefits and reflects Lilly’s current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, that the collaboration will succeed, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
&nbsp;

large_Artboard 2-100 11.jpg

medium_Artboard 2-100 11.jpg

small_Artboard 2-100 11.jpg

thumbnail_Artboard 2-100 11.jpg

Artboard 2-100 11.jpg

 Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

large_MicrosoftTeams-image (62).png

medium_MicrosoftTeams-image (62).png

small_MicrosoftTeams-image (62).png

thumbnail_MicrosoftTeams-image (62).png

MicrosoftTeams-image (62).png

EVA Pharma participates in the European Association for the Study of Diabetes’ annual conference

Top News

Are you a Healthcare professional?

Press Release

EVA Pharma's High-Containment and Biologics Facilities Achieve EU-GMP Certification, Paving the Way for Enhanced Access to Critical Medications

May 06, 2025

Top News

Press Release

May 06, 2025

Press Release

March 27, 2025

Press Release

February 05, 2025

Top News

Press Release

EVA Pharma's High-Containment and Biologics Facilities Achieve EU-GMP Certification, Paving the Way for Enhanced Access to Critical Medications

May 06, 2025